摘要
目的:探索厄贝沙坦联合氨氯地平治疗2型糖尿病合并高血压的疗效及对糖代谢和血压的影响。方法:选择2013年7月至2014年8月期间我院收治的2型糖尿病合并高血压患者50例,根据随机数字表法,将患者分成联合用药组和美托洛尔组。联合用药组口服厄贝沙坦和氨氯地平;美托洛尔组口服美托洛尔,疗程为3个月。分析比较治疗前后两组患者的空腹血糖(FBG)、空腹胰岛素(FINS)、胰岛素敏感指数(HOMA-IR)、收缩压(SBP)和舒张压(DBP)水平之间的差异,观察临床疗效。结果:治疗后,两组患者FBG、FINS、HOMA-IR、SBP和DBP水平较治疗前均有所下降,其中联合用药组下降得更明显(P<0.05),且治疗后联合用药组上述指标均显著低于美托洛尔组,差异均有统计学意义(P<0.05)。治疗后,联合用药组的治疗有效率为88.00%,显著高于美托洛尔组的48.00%,且差异具有统计学意义(P<0.05)。结论:厄贝沙坦联合氨氯地平治疗2型糖尿病合并高血压患者具有良好的疗效,可以改善血糖和血压情况,对于指导临床用药具有重要意义。
Objective： To explore the effect of irbesartan plus amlodipine in the treatment of type 2 diabetes mellitus combined with hypertension and their influence on glucose metabolism and blood pressure. Methods： A total of 50 patients with type 2 diabetes mellitus combined with hypertension, who were admitted to Second Artillery General Hospital of Beijing from July 2013 to August 2014, were randomly divided into combination group and metoprolol group. The combination group was treated with irbesartan plus amlodip- ine, while the metoprolol group was treated with rnetoprolol, the course of treatment was 3 months. Then the levels of fasting blood glu- cose（FBG）, fasting insulin（FINS）, insulin sensitive index（HOMA-IR）, systolic blood pressure（SBP） and diastolic blood pressure（DBP） before and after treatment were compared between the two groups, the Clinical effects were observed. Results： Compared with before treatment, the levels of FBG, FINS, HOMA IR, SBP and DBP in the two groups after treatment all decreased, the levels of the above in- dexes in the combination group after treatment were statistically lower than those in the metoprolol group, the differences were statistical- ly significant （P〈0.05）. The total effective rate（88.00%） in combination group was significantly higher than that（48.00%） in metoprolol group after treatment, the difference was statistically significant （P〈0.05）. Conclusion： Irbesartan plus amlodipine has a good effect in the treatment of type 2 diabetes mellitus combined with hypertension and can improve the blood glucose and blood pressure conditions, which has an important significance for guiding the clinical medication.
出处
《现代生物医学进展》
CAS
2015年第21期4149-4152,共4页
Progress in Modern Biomedicine
关键词
厄贝沙坦
氨氯地平
2型糖尿病
高血压
Irbesartan
Amlodipine
Type 2 diabetes mellitus
Hypertension
